EGFR and non-small cell lung carcinoma: The clinical trial results indicate that gefitinib belongs to the first generation of targeted therapeutic drugs, which can bind to the epidermal growth factor receptor, and has a good therapeutic effect on non-small cell lung cancer, breast cancer, etc6.